Inside this issue
Highlighted signals and events
During epidemiological week 45 (2–8 November 2026), WHO Public Health Intelligence (PHI) teams conducted digital event-based surveillance (DEBS) to support the early detection and assessment of potential public health threats. During the reporting period, 565 268 raw signals were screened across multiple sources. Of these, 23 signals were categorized for further assessment, including 22 unique signals. A total of 16 signals were escalated for further action.
During the reporting week, two new events were registered in the Event Management System (EMS): an event not yet diagnosed in Brazil and seasonal influenza in Vanuatu. Three Disease Outbreak News (DON) reports were published. A summary of the signal assessment metrics, selected signals of potential public health events, published information products and newly registered EMS events is provided below.
| Signals screened1 | Signals categorized2 | Unique signals3 | Signals escalated4 |
|---|---|---|---|
| 565 268 | 23 | 22 | 16 |
1 Signals screened: Total volume of raw signals reviewed from across multiple sources during the reporting period.
2 Signals categorized: Number of signals categorized for further detailed WHO assessment and actions during the reporting period.
3 Unique signals: Count of distinct signals after removing duplicate or repeated entries from different sources within the same epidemiological week.
4 Signals escalated: Subset of categorized signals that triggered escalation actions.
| Region | Hazard |
|---|---|
| Africa | Anthrax, unspecified Cholera Dengue Diphtheria Not yet diagnosed Yellow fever |
| Americas | Influenza due to identified avian or animal influenza virus Klebsiella pneumoniae Natural disaster |
| Eastern Mediterranean | Diphtheria |
| Europe | Chikungunya virus disease |
| South-East Asia | No publicly available signals identified |
| Western Pacific | Influenza due to identified avian or animal influenza virus |
5 The absence of listed signals indicates that no publicly available signals were identified during the reporting period and does not imply absence of signal activity overall.
6 Only new events registered during the defined period are included. Accordingly, changes to the disease/condition that occur after the data cut-off of 23:59 on 8 November 2026 will not be reflected in the description. The absence of events indicates that no publicly available newly reported events were identified during the reporting period and does not imply absence of event activity overall.
Schistosomiasis and soil-transmitted helminthiases: progress report, 2025
Background
Schistosomiasis and soil-transmitted helminthiases (STH) are neglected tropical diseases (NTDs) that remain major public health problems in many countries, particularly where access to safe water, sanitation and hygiene is limited. Schistosomiasis is caused by parasitic worms of the Schistosoma genus, while STH are mainly caused by Ascaris lumbricoides, Trichuris trichiura, Strongyloides stercoralis, and hookworms (Ancylostoma duodenale and Necator americanus). These infections can lead to anaemia, malnutrition, impaired growth and development, and, in the case of schistosomiasis, severe organ damage and genital disease.
The populations at greatest risk include preschool-aged children (pre-SAC, 1–4 years of age), school-aged children (SAC, 5–14 years of age), women of reproductive age and, for schistosomiasis, adults living in endemic communities, due to their occupations in link with contaminated water. To reduce morbidity and interrupt transmission, WHO recommends an integrated approach combining preventive chemotherapy (PC) with praziquantel for schistosomiasis, albendazole or mebendazole for Ascaris lumbricoides, Trichuris trichiura and hookworms, and ivermectin for Strongyloides stercoralis, alongside improvements in water, sanitation and hygiene (WASH), health education, and complementary interventions such as snail control for schistosomiasis.
Considerable progress has been made in reducing the burden of schistosomiasis and STH. The estimated STH burden measured in disability-adjusted life years (DALYs) had decreased from 3 million in 2010 to 1.7 million in 20231. In addition, the published data showed a 69.6% reduction in a global age-standardized STH prevalence in 2020 compared to 1990 with 75.8%, 59.9% and 82.9% reduction of infections due to Ascaris lumbricoides, Trichuris trichiura and hookworms respectively2. For schistosomiasis, the reduction of DALYs was low, 2.3 million in 2010 to 2.1 million in 20231.
The NTD road map places increasing emphasis not only on maintaining effective PC, but also on measuring programme impact, adapting the frequency of interventions to the epidemiological situation and progressing towards elimination of schistosomiasis and STH as a public health problem.
Status of countries in PC coverage in 2025
Schistosomiasis was endemic in 79 countries in 2025. Transmission of Schistosoma haematobium was confirmed in Cabo Verde, a country which was not previously endemic4. In 2025, PC was required for schistosomiasis in 50 countries with 129 million SAC and 107.1 million adults in need of treatment. For STH, PC was required in 84 countries: 247.6 million pre-SAC and 609 million SAC corresponding to approximately 856.6 million children across the two principal target groups.
This report documents global and regional progress in PC coverage for schistosomiasis and STH in 2025 and the impact of control intervention as reported by ministries of health to WHO. An online PC data portal5 holds details on each endemic country, including data reported by non-governmental organizations after validation by countries. Details of the methods used to collect and analyse data have been published.6 Data from the country reports for 2025 that had not been received at the time of publication will be made available on the PC data portal.
Numbers of people treated for schistosomiasis and STH in 2025
Provision of PC for schistosomiasis and STH in 2025, globally and by WHO region, is summarized in Table 1. In 2025, PC was provided to 77.4 million people (65.1 million SAC and 12.3 million adults) for schistosomiasis in 38 countries, reaching 32.8% global coverage (50.5% for SAC and 11.5% for adults). In addition, 466 488 children less than 5 years of age were reported to receive PC for schistosomiasis in two countries – 159 854 children in the United Republic of Tanzania (Zanzibar) and 306 634 children in the Philippines – using the current praziquantel formulation. Among the children requiring PC for STH, approximately 94 million pre-SAC and 302.2 million SAC were treated. This corresponded to global coverage of 37.9% among pre-SAC and 49.6% among SAC, with an overall treatment coverage of 46.2%.
In the African region, 63.6 million SAC and 10.7 million adults received PC for schistosomiasis, reaching a regional coverage of 33.4% (51.7% for SAC and 10.7% for adults). For STH, 95.4 million children in need of treatment were covered by PC (39.1%) in 2025 (17.3% for pre-SAC and 49.4% for SAC). Only 11 and 27 countries out of 37 reported the treatment of pre-SAC and SAC respectively.
| WHO Region | |||||||
|---|---|---|---|---|---|---|---|
| African | The Americas | South-East Asia | European | Eastern Mediterranean | Western Pacific | Global | |
| Soil-transmitted helminthiases | |||||||
| Number of countries requiring PC | 37 | 16 | 7 | 3 | 6 | 15 | 84 |
| Number of countries with no data available | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Preschool-aged children | |||||||
| Number of countries reporting | 11 | 4 | 3 | 0 | 2 | 6 | 26 |
| Number of preschool-aged children requiring PC | 78 695 495 | 7 106 822 | 111 011 785 | 1 881 486 | 16 269 524 | 32 666 442 | 247 631 554 |
| Number of preschool-aged children requiring PC treateda | 13 644 338 | 1 117 738 | 53 578 405 | 0 | 6 893 033 | 18 722 522 | 93 956 036 |
| Coverage (%) | 17.3 | 15.7 | 48.3 | 0 | 42.4 | 57.3 | 37.9 |
| School-aged children | |||||||
| Number of countries reporting | 27 | 5 | 4 | 1 | 3 | 7 | 47 |
| Number of school-aged children requiring PC | 165 438 031 | 18 474 956 | 303 503 497 | 3 497 249 | 35 869 426 | 82 251 990 | 609 035 149 |
| Number of school-aged children requiring PC treateda | 81 789 419 | 5 300 024 | 139 851 273 | 25 283 | 15 683 583 | 59 508 504 | 302 158 086 |
| Coverage (%) | 49.4 | 28.7 | 46.1 | 0.7 | 43.7 | 72.3 | 49.6 |
| Total number of children | |||||||
| Total number of children requiring PC | 244 133 526 | 25 581 778 | 414 515 282 | 5 378 735 | 52 138 950 | 114 918 432 | 856 666 703 |
| Total number of children requiring PC and treateda | 95 433 757 | 6 417 762 | 193 429 678 | 25 283 | 22 576 616 | 78 231 026 | 396 114 122 |
| Coverage (%) | 39.1 | 25.1 | 46.7 | 0.5 | 43.3 | 68.1 | 46.2 |
| Schistosomiasis | |||||||
| Number of countries requiring PC | 41 | 2 | 0 | 0 | 3 | 4 | 50 |
| School-aged children | |||||||
| Number of countries reporting | 31 | 1 | 0 | 0 | 2 | 4 | 38 |
| Number of school-aged children requiring PC | 123 057 715 | 305 286 | 0 | 0 | 4 282 464 | 1 352 526 | 128 997 991 |
| Number of school-aged children requiring PC treated | 63 592 850 | 569 | 0 | 0 | 649 568 | 920 591 | 65 163 578 |
| Coverage (%) | 51.7 | 0.2 | 0 | 0 | 15.2 | 68.1 | 50.5 |
| Adults | |||||||
| Number of countries reporting | 19 | 1 | 0 | 0 | 1 | 4 | 25 |
| Number of adults requiring PC | 99 628 338 | 1 283 812 | 0 | 0 | 3 787 454 | 2 374 741 | 107 074 345 |
| Number of adults requiring PC treated | 10 676 346 | 3 381 | 0 | 0 | 828 | 1 601 589 | 12 282 144 |
| Coverage (%) | 10.7 | 0.3 | 0 | 0 | 0.02 | 67.4 | 11.5 |
| Total number of people | |||||||
| Total number of people requiring PC | 222 686 053 | 1 589 098 | 0 | 0 | 8 069 918 | 3 727 267 | 236 072 336 |
| Total number of people requiring PC and treated | 74 269 196 | 3 950 | 0 | 0 | 650 396 | 2 522 180 | 77 445 722 |
| Coverage (%) | 33.4 | 0.3 | 0 | 0 | 8.1 | 67.7 | 32.8 |
a Number treated in areas requiring PC is the number of children received PC for STH at least once in the reporting year in areas where baseline prevalence of infection is ≥20% or impact prevalence is ≥2%.
In the Americas, no PC for schistosomiasis was conducted in Venezuela (Bolivarian Republic of), while Brazil reported treatment of 569 SAC and 3381 adults. For STH, among the16 endemic countries, 11 had conducted PC at least once in the last five years and for 2025, only five countries reported PC for STH treating 6.4 million children representing 25.1% regional coverage (15.7% for pre-SAC and 28.7% for SAC). Four endemic countries (Bolivia [Plurinational State of], Dominica, Panama and Saint Vincent and the Grenadines) had not reported any treatment to WHO for the last 10 years.
In the Eastern Mediterranean region, among the three countries requiring PC for schistosomiasis, Somalia and Yemen reported treatments while Sudan has not implemented PC for schistosomiasis. Egypt, after tremendous long-term effort, has decreased the prevalence of schistosomiasis to a level where it could be considered as not requiring PC. The country is now implementing a test-and-treat strategy. For STH, four countries (Afghanistan, Pakistan, Somalia and the Syrian Arab Republic) out of six STH endemic countries reported treatment in 2025 with a total regional coverage of 43.3%.
In the European region, only one of the three countries endemic for STH, Kyrgyzstan, reported treatment of 25 283 SAC which represented 0.5% of the total children in need of PC in the region.
In the South-East Asia region, PC for STH was conducted in four out of the seven countries requiring mass treatment, reaching 193.4 million children with a regional coverage of 46.7%. Bangladesh, the highest-burden country for STH (more than 55 million children in need of PC) did not conduct mass drug administration (MDA) for STH in 2025, which corresponds to a decrease in regional coverage (65.7% in 2024). Bhutan and the Democratic People’s Republic of Korea did not report on PC treatment in 2025.
In the Western Pacific region, all four schistosomiasis endemic countries (Cambodia, Indonesia, Lao People’s Democratic Republic and the Philippines) submitted reports, with a total of 2.5 million people treated, representing 67.7% regional coverage. Among the 15 endemic countries on the region for STH, only seven reported treatment data, with a total of 78.2 million children treated (68.1%). Among the eight countries that did not report, four of them (Marshall Islands, Micronesia [Federated States of], Naoero, and Solomon Islands) had not reported any treatment data for the last 5 years.
In 2025, 17 of the 38 countries that implemented PC for schistosomiasis achieved ≥75% national coverage for SAC, and 14 of the 47 countries that implemented PC for STH reached the 75% coverage target for SAC.
Table 2 shows progress in countries that require PC for STH and schistosomiasis in 2025 in providing PC for SAC, the age group for which drugs are donated.
| Countries not implementing PC or not reporting for SAC in 2025 | Countries implementing PC for SAC in 2025 with <75% national coverage | Countries implementing PC for SAC in 2025 with ≥75% national coverage |
|---|---|---|
| Soil-transmitted helminthiases | ||
| Afghanistana, Bangladesha, Bhutanb, Bolivia (Plurinational State of)b, Botswanaa, Brazila, Cabo Verdea, Comorosa, Democratic People's Republic of Koreab, Dominicab, Equatorial Guineaa, Eswatinia, Fijib, Gambiac, Guatemalab, Guyanab, Haitib, Hondurasb, Iraqa, Lesothoa, Malawia, Marshall Islandsb, Micronesia (Federated States of)b, Naoerob, Panamab, Papua New Guineaa, Perub, Saint Vincent and the Grenadinesb, Solomon Islandsb, South Africaa, Tajikistana, Tongab, Tuvalub, Uzbekistanb, Venezuela (Bolivarian Republic of)b, Yemena, Zambiaa | Angola, Benin, Burundi, Cameroon, Central African Republic, Chad, Colombia, Congo, Democratic Republic of the Congo, Gabon, Guinea-Bissau, India, Kenya, Kiribati, Kyrgyzstan, Lao People's Democratic Republic, Liberia, Mozambique, Myanmar, Nepal, Nigeria, Paraguay, Philippines, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, Syrian Arab Republic, Togo, Uganda, United Republic of Tanzania, Vanuatu, Zimbabwe | Cambodia, Côte d'Ivoire, Dominican Republic, El Salvador, Ethiopia, Guinea, Indonesia, Madagascar, Nicaragua, Pakistan, Rwanda, South Sudan, Timor-Leste, Viet Nam |
| 37 | 33 | 14 |
| Schistosomiasis | ||
| Botswanaa, Equatorial Guineaa, Eritreaa, Eswatinia, Gabona, Gambiaa, Mozambiquea, Namibiaa, South Africaa, Sudana, Venezuela (Bolivarian Republic of)a, Zambiaa | Angola, Benin, Brazil, Central African Republic, Ghana, Indonesia, Kenya, Liberia, Malawi, Niger, Nigeria, Philippines, Rwanda, Sao Tome and Principe, Sierra Leone, Somalia, South Sudan, United Republic of Tanzania, Togo, Uganda, Yemen | Burkina Faso, Burundi, Cambodia, Cameroon, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Ethiopia, Guinea, Guinea-Bissau, Lao People's Democratic Republic, Madagascar, Mali, Mauritania, Senegal, Zimbabwe |
| 12 | 21 | 17 |
a Countries did not implement PC for SAC in 2025 for the disease
b Countries have not reported on PC implementation in 2025
c Countries submitted report on PC implementation in 2025, which is under validation
Progress towards the 2030 NTD road map targets
The main goal of the programmes to control schistosomiasis and STH is to eliminate morbidity associated with these diseases in the target population by reducing the prevalence of moderate- and heavy-intensity infections and the overall prevalence of infection mainly by PC with praziquantel and either albendazole or mebendazole.
WHO recommends to endemic countries a collection of parasitological data after five years of PC with effective coverage (≥75%) to show the impact of the programme and revise their PC strategy according to the new epidemiological situation. For STH, in countries requiring PC in 2025, 472 implementation units (IU) suspended PC or are implementing events-based PC following the results of impact assessment surveys and most of them (439 IU) are in the African region. The road map target for STH and schistosomiasis is the elimination of both diseases as a public health problem, which is defined as a cumulative prevalence of moderate and heavy intensity infections of < 2% for STH and <1% for schistosomiasis. In the African region, four countries (Burundi, Rwanda, Togo and Mauritius) and seven countries (Burkina Faso, Ghana, Mali, Namibia, Niger, the Seychelles and Zimbabwe) are preparing elimination dossiers for schistosomiasis and STH respectively. These are supported by the Expanded Special Project for the Elimination of Neglected Tropical Diseases (ESPEN), which organised a workshop on 19–21 May 2026 to help the above countries prepare high-quality, WHO-compliant elimination dossiers. It is expected that these will be finalised and submitted in 2027.
In December 2025, the regional office of the Americas organised an expert meeting to review the status of schistosomiasis transmission and set a plan for preparing the schistosomiasis elimination dossier for submission. A dossier review will be undertaken to remove Saint Martin and Montserrat from the list of endemic countries and territories, and the region will provide support for the preparation of elimination dossiers for other countries.
Algeria, Indonesia, Egypt and Iran (Islamic Republic of) have submitted dossiers to be recognised as having eliminated schistosomiasis as a public health problem and interrupted its transmission (in the case of Iran [Islamic Republic of]). These are currently under review.
Schistosomiasis and STH 2026 global programme review meeting
WHO organized a review meeting on schistosomiasis and STH programmes on 25–27 March 2026 in Addis Ababa, Ethiopia, to review progress and discuss challenges towards achieving the WHO 2030 NTD road map targets for schistosomiasis and STH. Participants at the meeting, which included national programme managers, WHO regional focal points and partners, recommended the following urgent actions:
- Acceleration and increase of treatment coverage to optimize the use of donated drug to reduce the prevalence and intensity of schistosomiasis and STH before 2030. This will enable endemic countries to reduce the population in need of treatment and the number of tablets needed after 2030 given the uncertainty around future medicine donations for STH.
- Implementation of impact assessment surveys as their results are essential to allowing programmes to modify resource allocation and treatment frequency as disease epidemiology changes. The objective is to ensure that treatment is delivered effectively where it remains needed.
- Integration of schistosomiasis and STH deworming into national health systems to ensure sustainable delivery as donor support declines.
- Adaptation and development of strategies that will ensure continuity of care for people and communities in need of treatment, for the sustainability of schistosomiasis and STH programmes with the decline of external funding.
- Institutionalization of PC within national health systems, strengthening domestic ownership and financing, improvement of community engagement and behaviour change; and the scaling up of WASH and One Health approaches were suggested as strategies for sustainability.
Discussion
The number of people who were reported to require PC for schistosomiasis globally in 2025 was 236.1 million (Figure 2). This represents a reduction of 17.6 million people (67% adults and 33% SAC) requiring PC for schistosomiasis compared to 2024, due mainly to lower administrative level estimation of the target by programmes. Globally, 77.4 million people received treatment for schistosomiasis in 2025, for a coverage of 32.8%. Compared to 2024, there is a reduction of 23 million of the number of treatments, corresponding to 22.9%. This reduction concerns mostly SAC (78%). Despite a higher number of countries who implemented PC for schistosomiasis in 2025, there was a reduction of the number of IUs targeted for treatment due the lack of funding. The majority of the treatment has been provided in the African region (95.9%). Globally, 12 countries requiring PC for schistosomiasis have not conducted MDA in 2025 (10 in the African, one in the Americas, and one in the Eastern Mediterranean regions); among them Mozambique, Zambia and Sudan, which have substantial numbers of people requiring PC. Global coverage of treatment for adults remains low (11.5%) even though 70.3% of countries are reporting implementing adult treatment during PC (25 of the 38 countries reporting). In line with WHO schistosomiasis elimination guidelines, treatment of pre-SAC has been conducted by two countries who reported the treatment of 466 488 pre-SAC using the current praziquantel formulation.

Globally, in 2025 the population in need of PC for STH was reduced by 25.6 million compared to 2024 (Figure 3). The number of pre-SAC and SAC reported as treated for STH also declined from 507 million in 2024 to 396.1 million in 2025. Consequently, the global treatment coverage decreased from 57.5% to 46.2%. The largest regional declines were observed in the South-East Asia and African regions. In South-East Asia, this could be explained by the fact that in 2025, no PC was conducted in Bangladesh and the Democratic People’s Republic of Korea did not report treatment data; and there was a reduction of treatments in India, with a decline of the proportion of number of children treated from 64.4% in 2024 to 54.0% in 2025. In the African region, treatment coverage decreased from 49.6% in 2024 to 39.1% in 2025. This reduction was driven mainly by the decline in the reported proportion of children dewormed in Nigeria from 43.5% to 26.2%. Changes in this country’s pharmaceutical regulatory and procurement environment contributed to constraints in the availability of albendazole and mebendazole for planned PC activities. Consequently, the number of children who could be reached was reduced. This situation highlights the broader risk of transition for large-scale PC programmes.

Where domestic resources or procurement systems are insufficient to meet programme requirements, pragmatic transitional arrangements are necessary to avoid programme delivery disruptions. These arrangements should include continued access to drug donations and other procurement options. Ensuring the continuity of the supply of medicines during such transitions is essential in order to protect previous gains and maintain progress towards eliminating soil-transmitted helminthiasis and other neglected tropical diseases as public health problems. Progress towards greater national ownership and self-reliance requires sustainable financing and procurement mechanisms to ensure continued access to quality-assured medicines.
Conclusion
Globally, compared to 2024, there is a reduction of the number of people receiving PC for schistosomiasis (-22.9%) and STH (-22%) in 2025 as a consequence of the global reduction of development aid. New strategies such as integration of PC with other public health interventions is essential to ensure that PC is provided to people in need in all endemic areas of countries.
Global Health Estimates 2023: Disease burden by Cause, Age, Sex, by Country and by Region, 2000–2023. Geneva, World Health Organization; 2026 ↩︎
Chen J, Gong Y, Chen Q, Li S, Zhou Y. Global burden of soil-transmitted helminth infections, 1990–2021. Infect Dis Poverty. 2024;13:77. https://doi.org/10.1186/s40249-024-01238-9 ↩︎
Maia da Costa V et al. Urinary schistosomiasis outbreak in Cabo Verde: the first description in the country, May–June, 2022. PAMJ One Health. 2024;13:13. https://doi.org/10.11604/pamj-oh.2024.13.13.41435 ↩︎
Preventive chemotherapy data portal. Geneva: World Health Organization; 2018 (https://www.who.int/data/preventive-chemotherapy, accessed October 2026). ↩︎
Soil-transmitted helminthiases: estimates of the number of children needing preventive chemotherapy and number treated, 2009. Wkly Epidemiol Rec. 2011;86(25):257–266. ↩︎



